ArticleNutrients2021
Biological Effects of XyloCore, a Glucose Sparing PD Solution, on Mesothelial Cells: Focus on Mesothelial-Mesenchymal Transition, Inflammation and Angiogenesis.
Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Management of Hypertension in Patients Undergoing Peritoneal Dialysis: A Narrative Review.Cureus · 2026Review
- Innovations in peritoneal dialysis fluid: biocompatible formulations and expanded therapeutic applications.Renal failure · 2025Review
- Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe?Cardiovascular research · 2025Review
- Kidney Involvement in SARS-CoV-2 Infection: Peritoneal Dialysis as the Preferred Modality.Vaccines · 2025Review
- Current Progress in Peritoneal Dialysis: A Narrative Review of Progress in Peritoneal Dialysis Fluid.Life (Basel, Switzerland) · 2025Review
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- The future of peritoneal dialysis.Clinical kidney journal · 2024Article
- Glucose-Free Solutions Mediated Inhibition of Oxidative Stress and Oxidative Stress-Related Damages in Peritoneal Dialysis: A Promising Solution.Life (Basel, Switzerland) · 2024Article
- Coupling Osmotic Efficacy with Biocompatibility in Peritoneal Dialysis: A Stiff Challenge.International journal of molecular sciences · 2024Review
- Peritoneal fibrosis: from pathophysiological mechanism to medicine.Frontiers in physiology · 2024Review
- Development of a clinical automatic calculation of hypoglycemia during hemodialysis risk in patients with diabetic nephropathy.Diabetology & metabolic syndrome · 2023Article
- Substrate Type and Concentration Differently Affect Colon Cancer Cells Ultrastructural Morphology, EMT Markers, and Matrix Degrading Enzymes.Biomolecules · 2022Article
- How peritoneal dialysis transforms the peritoneum and vasculature in children with chronic kidney disease-what can we learn for future treatment?Molecular and cellular pediatrics · 2022Review
- Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis.International journal of molecular sciences · 2022Review
- Heparanase regulates EMT and cancer stem cell properties in prostate tumors.Frontiers in oncology · 2022Article
- Steviol glycosides as an alternative osmotic agent for peritoneal dialysis fluid.Frontiers in pharmacology · 2022Article
- Aging of the Peritoneal Dialysis Membrane.Frontiers in physiology · 2022Review
- How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without Jeopardizing the Patient's Health).International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-based solutions remain the most used osmotic agents in peritoneal dialysis (PD), but unavoidably they contribute to the loss of peritoneal filtration capacity. Here, we evaluated at a molecular level the effects of XyloCore, a new PD solution with a low glucose content, in mesothelial and endothelial cells. Cell viability, integrity of mesothelial and endothelial cell membrane, activation of mesothelial and endothelial to mesenchymal transition programs, inflammation, and angiogenesis were evaluated by several techniques. Results showed that XyloCore preserves mesothelial and endothelial cell viability and membrane integrity. Moreover XyloCore, unlike glucose-based solutions, does not exert pro-fibrotic, -inflammatory, and -angiogenic effects. Overall, the in vitro evidence suggests that XyloCore could represent a potential biocompatible solution promising better outcomes in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.